Responses
Oral Presentations
Still breaking news on TNF inhibitors in rheumatoid arthritis
OP0021 Efficacy and safety results of a phase iii study comparing fkb327, an adalimumab biosimilar, with the adalimumab reference product in patients with active rheumatoid arthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.